Status:
COMPLETED
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Myocarditis
Eligibility:
All Genders
16-65 years
Brief Summary
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
Detailed Description
Considering previous reports of cardiovascular adverse events, passive surveillance might not identify all myocarditis/myopericarditis cases after COVID-19 vaccination and it is possible that a mild/s...
Eligibility Criteria
Inclusion
- individuals working at the University Hospital Basel, Switzerland
- informed consent available
- 16-65 years old
Exclusion
- Refusal to participate at the study
- Cardiac events or cardiac surgery within 30 days prior to study (as these could result in prolonged hs-cTnT elevations and interfere with the diagnosis of myocarditis
Key Trial Info
Start Date :
December 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2022
Estimated Enrollment :
835 Patients enrolled
Trial Details
Trial ID
NCT05438472
Start Date
December 10 2021
End Date
April 20 2022
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Department of Cardiology
Basel, Switzerland, 4031